TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07235293: A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Sponsor: Kahr Bio Australia Pty Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,049,200

Rescue Site Savings

+$2,032,800

Unlock Full NCT07235293 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07235293 Rescue Dossier →